Eisai Co., Ltd.

Eisai Co., Ltd. is a prominent Japanese pharmaceutical company engaged in the research, development, manufacture, and marketing of healthcare products. Known for its significant contributions to drug discovery and development, Eisai primarily focuses on therapeutic areas such as oncology, neurology, and gastrointestinal diseases. The company is renowned for developing Aricept, a leading treatment for Alzheimer's disease, showcasing its expertise in neurology. Eisai's operations extend across multiple sectors in healthcare, with a strong emphasis on innovation and patient-centric solutions. Its business model integrates cutting-edge research with robust clinical development through global partnerships and collaborations. By leveraging biopharmaceutical advancements, Eisai aims to address unmet medical needs and improve patient outcomes internationally. In the financial markets, Eisai Co., Ltd. plays a crucial role as a major player in the pharmaceutical industry, contributing to advancements in medical research and treatment options. Its commitment to research excellence and strategic global expansion underscores its status as a leader in the healthcare sector, impacting both local and international markets with its future-focused therapeutic developments.

CEO

Mr. Haruo Naito

Employees

10,917

Website

eisai.co.jp